Tumor glycolysis as a target for cancer therapy: Progress and prospects

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Ganapathy Kanniappan, Shanmugasundaram ^a   Geschwind, Jean Francois H ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Antiglycolytic agents; Cancer metabolism; Chemotherapy; Glycolysis

Indexed keywords

CELL NUCLEUS DNA; FRUCTOSE 1,6 BISPHOSPHATE; FUMARIC ACID; GLUCOSE 6 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; ISOCITRATE DEHYDROGENASE; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL DNA; OXIDOREDUCTASE; PHOSPHOENOLPYRUVATE; PYRUVATE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SUCCINATE DEHYDROGENASE;

CANCER THERAPY; CARCINOGENESIS; CITRIC ACID CYCLE; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; MITOCHONDRIAL GENE; MITOCHONDRIAL RESPIRATION; MUTATION; NEGATIVE FEEDBACK; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PHENOTYPE; REVIEW; TUMOR GLYCOLYSIS;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYMES; GLYCOLYSIS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84888798201     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-152     Document Type: Review

References (121)

1. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001, 2(3):157-164. 10.1016/S1470-2045(00)00257-6, 11902566.
2. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314. 0036-8075 (Print), 10.1126/science.123.3191.309, 13298683.
3. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124(3215):269-270. PMID- 13471593 OWN - NLM STAT- MEDLINE (0036-8075 (Print)).
4. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 2004, 4(3):449-457. 10.1586/14737140.4.3.449, 15161443.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
6. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005, 202(3):654-662. 10.1002/jcp.20166, 15389572.
7. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25(34):4633-4646. 10.1038/sj.onc.1209597, 16892078.
8. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008, 283(42):28106-28114. 10.1074/jbc.M803508200, 2661383, 18718909.
9. Fanciulli M, Bruno T, Giovannelli A, Gentile FP, Di Padova M, Rubiu O, Floridi A. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine. Clin Cancer Res 2000, 6(4):1590-1597.
10. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134(5):703-707. 10.1016/j.cell.2008.08.021, 18775299.
11. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med 2011, 89(3):205-212. 10.1007/s00109-011-0730-x, 3345191, 21301795.
12. Birsoy K, Sabatini DM, Possemato R. Untuning the tumor metabolic machine: targeting cancer metabolism: a bedside lesson. Nat Med 2012, 18(7):1022-1023. 10.1038/nm.2870, 22772555.
13. Dang CV. Links between metabolism and cancer. Genes Dev 2012, 26(9):877-890. 10.1101/gad.189365.112, 3347786, 22549953.
14. Granchi C, Minutolo F. Anticancer agents that counteract tumor glycolysis. Chem Med Chem 2012, 7(8):1318-1350. 10.1002/cmdc.201200176, 3516916, 22684868.
15. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21(3):297-308. 10.1016/j.ccr.2012.02.014, 3311998, 22439925.
16. Cuperlovic-Culf M, Culf AS, Touaibia M, Lefort N. Targeting the latest hallmark of cancer: another attempt at 'magic bullet' drugs targeting cancers' metabolic phenotype. Future Oncol 2012, 8(10):1315-1330. 10.2217/fon.12.121, 23130930.
17. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013, 4:e532. 10.1038/cddis.2013.60, 3613838, 23470539.
18. Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 2013, 45:e45. 10.1038/emm.2013.85, 3809361, 24091747.
19. Zhang Y, Yang JM. Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol Ther 2013, 14(2):81-89. 10.4161/cbt.22958, 23192270.
20. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED. A mitochondria-K + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11(1):37-51. 10.1016/j.ccr.2006.10.020, 17222789.
21. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G, Huang P. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 2012, 22(2):399-412. 10.1038/cr.2011.145, 3257361,3257361, 21876558.
22. Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y, Huang P. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol 2012, 10(5):e1001326. 10.1371/journal.pbio.1001326, 3348157, 22589701.
23. Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012, 12(10):685-698. 10.1038/nrc3365, 23001348.
24. Cavalli LR, Varella-Garcia M, Liang BC. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ 1997, 8(11):1189-1198.
25. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989, 246(4929):500-503. 10.1126/science.2814477, 2814477.
26. de Souza AC, Justo GZ, de Araujo DR, Cavagis AD. Defining the molecular basis of tumor metabolism: a continuing challenge since Warburg's discovery. Cell Physiol Biochem 2011, 28(5):771-792. 10.1159/000335792, 22178931.
27. Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science 2001, 292(5516):504-507. 10.1126/science.1058079, 11283355.
28. Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, Gao G, Zhang A, Xia X, Brasher H, Widger W, Ellis LM, Weihua Z. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res 2012, 72(1):304-314. 10.1158/0008-5472.CAN-11-1674, 3601736, 22084398.
29. Locasale JW, Cantley LC. Altered metabolism in cancer. BMC Biol 2010, 8:88. 10.1186/1741-7007-8-88, 2892450, 20598111.
30. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4(11):891-899. 10.1038/nrc1478, 15516961.
31. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011, 27:441-464. 10.1146/annurev-cellbio-092910-154237, 21985671.
32. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008, 18(1):54-61. 10.1016/j.gde.2008.02.003, 2476215, 18387799.
33. Backos DS, Franklin CC, Reigan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol 2012, 83(8):1005-1012. 10.1016/j.bcp.2011.11.016, 22138445.
34. Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM, Domenicotti C. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013, 2013:972913. 3673338, 23766865.
35. Pitroda SP, Wakim BT, Sood RF, Beveridge MG, Beckett MA, MacDermed DM, Weichselbaum RR, Khodarev NN. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med 2009, 7:68. 10.1186/1741-7015-7-68, 2780454, 19891767.
36. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 2012, 53(3):421-436. 10.1016/j.freeradbiomed.2012.05.006, 22580150.
37. Xu X, Zur Hausen A, Coy JF, Lochelt M. Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 2009, 124(6):1330-1337. 10.1002/ijc.24078, 19065656.
38. Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA, Ha PK, Califano JA. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 2010, 16(3):857-866. 10.1158/1078-0432.CCR-09-2604, 2824550, 20103683.
39. Wanka C, Steinbach JP, Rieger J. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem 2012, 287(40):33436-33446. 10.1074/jbc.M112.384578, 3460445, 22887998.
40. Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, Perl AE, Carroll M, Tuttle SW, Thompson CB. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 2010, 29(20):2962-2972. 10.1038/onc.2010.67, 2874611, 20228846.
41. Monteleone F, Rosa R, Vitale M, D'Ambrosio C, Succoio M, Formisano L, Nappi L, Romano MF, Scaloni A, Tortora G, Bianco R, Zambrano N. Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics 2013, 13(5):866-877. 10.1002/pmic.201200303, 23281225.
42. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 2005, 30(3):142-150. 10.1016/j.tibs.2005.01.005, 15752986.
43. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002, 277(9):7610-7618. 10.1074/jbc.M109950200, 11751859.
44. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004, 16(5):819-830. 10.1016/j.molcel.2004.11.014, 15574336.
45. Seidler NW. GAPDH and intermediary metabolism. Adv Exp Med Biol 2013, 985:37-59. 10.1007/978-94-007-4716-6_2, 22851446.
46. Seidler NW. Basic biology of GAPDH. Adv Exp Med Biol 2013, 985:1-36. 10.1007/978-94-007-4716-6_1, 22851445.
47. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget 2012, 3(9):940-953. 3660062, 22964488.
48. Wu S, Le H. Dual roles of PKM2 in cancer metabolism. Acta Biochim Biophys Sin (Shanghai) 2013, 45(1):27-35. 10.1093/abbs/gms106, 23212076.
49. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452(7184):230-233. 10.1038/nature06734, 18337823.
50. Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab 2012, 23(11):560-566. 10.1016/j.tem.2012.06.010, 3466350, 22824010.
51. Luo W, Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011, 2(7):551-556. 3248177, 21709315.
52. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, Aldape K, Cantley LC, Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 2012, 14(12):1295-1304. 10.1038/ncb2629, 3511602, 23178880.
53. Filipp FV. Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulator. J Carcinog 2013, 12:14. 10.4103/1477-3163.115423, 3746496, 23961261.
54. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012, 150(4):685-696. 10.1016/j.cell.2012.07.018, 3431020, 22901803.
55. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011, 480(7375):118-122. 3235705, 22056988.
56. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452(7184):181-186. 10.1038/nature06667, 18337815.
57. Diaz-Ruiz R, Averet N, Araiza D, Pinson B, Uribe-Carvajal S, Devin A, Rigoulet M. Mitochondrial oxidative phosphorylation is regulated by fructose 1,6-bisphosphate. A possible role in Crabtree effect induction?. J Biol Chem 2008, 283(40):26948-26955. 10.1074/jbc.M800408200, 18682403.
58. Wartenberg M, Richter M, Datchev A, Gunther S, Milosevic N, Bekhite MM, Figulla HR, Aran JM, Petriz J, Sauer H. Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J Cell Biochem 2010, 109(2):434-446.
59. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 2011, 11:312. 10.1186/1471-2407-11-312, 3157459, 21787388.
60. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY, Sasaguri Y, Nishizawa S, Kohno K. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 2011, 102(5):1007-1013. 10.1111/j.1349-7006.2011.01908.x, 21306479.
61. Masters C. Cellular differentiation and the microcompartmentation of glycolysis. Mech Ageing Dev 1991, 61(1):11-22. 10.1016/0047-6374(91)90003-I, 1779698.
62. Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, Brock E, Siow D, Wattenberg B, Telang S, Chesney J. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem 2009, 284(36):24223-24232. 10.1074/jbc.M109.016816, 2782016, 19473963.
63. Demarse NA, Ponnusamy S, Spicer EK, Apohan E, Baatz JE, Ogretmen B, Davies C. Direct binding of glyceraldehyde 3-phosphate dehydrogenase to telomeric DNA protects telomeres against chemotherapy-induced rapid degradation. J Mol Biol 2009, 394(4):789-803. 10.1016/j.jmb.2009.09.062, 2789664, 19800890.
64. Harada N, Yasunaga R, Higashimura Y, Yamaji R, Fujimoto K, Moss J, Inui H, Nakano Y. Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells. J Biol Chem 2007, 282(31):22651-22661. 10.1074/jbc.M610724200, 17553795.
65. Popanda O, Fox G, Thielmann HW. Modulation of DNA polymerases alpha, delta and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim Biophys Acta 1998, 1397(1):102-117. 10.1016/S0167-4781(97)00229-7, 9545551.
66. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000, 60(4):916-921.
67. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118(12):3930-3942. 2582933, 19033663.
68. Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech 2011, 4(6):727-732. 10.1242/dmm.007724, 3209642, 22065843.
69. Semenza GL. Tumor metabolism: cancer cells give and take lactate. J Clin Invest 2008, 118(12):3835-3837. 2582934, 19033652.
70. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012, 44(1):127-139. 10.1007/s10863-012-9428-1, 22407107.
71. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 2009, 92(3):329-333. 10.1016/j.radonc.2009.06.025, 19604589.
72. Hussien R, Brooks GA. Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines. Physiol Genomics 2011, 43(5):255-264. 10.1152/physiolgenomics.00177.2010, 3068517, 21177384.
73. Hugo-Wissemann D, Anundi I, Lauchart W, Viebahn R, de Groot H. Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes. Hepatology 1991, 13(2):297-303. 10.1002/hep.1840130215, 1847350.
74. Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, Hamano K, Okita K, Sakaida I, Nakamura K. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007, 30(4):849-855.
75. Yeh CS, Wang JY, Chung FY, Lee SC, Huang MY, Kuo CW, Yang MJ, Lin SR. Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers. Oncol Rep 2008, 19(1):81-91.
76. Rimpi S, Nilsson JA. Metabolic enzymes regulated by the Myc oncogene are possible targets for chemotherapy or chemoprevention. Biochem Soc Trans 2007, 35(Pt 2):305-310.
77. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 2005, 7(4):324-330. 10.1593/neo.04430, 1501147, 15967109.
78. Rodriguez-Enriquez S, Gallardo-Perez JC, Aviles-Salas A, Marin-Hernandez A, Carreno-Fuentes L, Maldonado-Lagunas V, Moreno-Sanchez R. Energy metabolism transition in multi-cellular human tumor spheroids. J Cell Physiol 2008, 216(1):189-197. 10.1002/jcp.21392, 18264981.
79. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501. 10.1038/nrc839, 12094235.
80. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64(11):3892-3899. 10.1158/0008-5472.CAN-03-2904, 15172999.
81. Csibi A, Blenis J. Appetite for destruction: the inhibition of glycolysis as a therapy for tuberous sclerosis complex-related tumors. BMC Biol 2011, 9:69. 10.1186/1741-7007-9-69, 3198763, 22018140.
82. Jiang X, Kenerson H, Aicher L, Miyaoka R, Eary J, Bissler J, Yeung RS. The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. Am J Pathol 2008, 172(6):1748-1756. 10.2353/ajpath.2008.070958, 2408433, 18511518.
83. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010, 39(2):171-183. 10.1016/j.molcel.2010.06.022, 2946786, 20670887.
84. Klement RJ, Kammerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer?. Nutr Metab (Lond) 2011, 8:75. 10.1186/1743-7075-8-75, 3267662, 22029671.
85. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 2012, 11(8):1672-1682. 10.1158/1535-7163.MCT-12-0131, 22689530.
86. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25(34):4777-4786. 10.1038/sj.onc.1209603, 3385868, 16892090.
87. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the " Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 2009, 19(1):17-24. 10.1016/j.semcancer.2008.11.006, 2714668, 19101634.
88. Price GS, Page RL, Riviere JE, Cline JM, Thrall DE. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs. Cancer Chemother Pharmacol 1996, 38(2):129-135. 10.1007/s002800050460, 8616902.
89. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004, 53(2):116-122. 10.1007/s00280-003-0724-7, 14605866.
90. Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN, Lampidis TJ. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther 2007, 6(11):3049-3058. 10.1158/1535-7163.MCT-07-0310, 18025288.
91. Zhong D, Liu X, Schafer-Hales K, Marcus AI, Khuri FR, Sun SY, Zhou W. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther 2008, 7(4):809-817. 10.1158/1535-7163.MCT-07-0559, 18413794.
92. Zhong D, Xiong L, Liu T, Liu X, Liu X, Chen J, Sun SY, Khuri FR, Zong Y, Zhou Q, Zhou W. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem 2009, 284(35):23225-23233. 10.1074/jbc.M109.005280, 2749096, 19574224.
93. Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther 2007, 6(2):732-741. 10.1158/1535-7163.MCT-06-0407, 17308069.
94. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004, 64(1):31-34. 10.1158/0008-5472.CAN-03-3294, 14729604.
95. Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 2009, 5(5):581-585. 10.2217/fon.09.44, 19519197.
96. Chesney J. 6-Phosphofructo-2-Kinase/fructose-2,6-Bisphosphatase and Tumor Cell Glycolysis. Curr Opin Clin Nutr Metab Care 2006, 9(5):535-539. 10.1097/01.mco.0000241661.15514.fb, 16912547.
97. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 2008, 7(1):110-120. 10.1158/1535-7163.MCT-07-0482, 18202014.
98. Thornalley PJ, Rabbani N. Glyoxalase in tumourigenesis and multidrug resistance. Semin Cell Dev Biol 2011, 22(3):318-325. 10.1016/j.semcdb.2011.02.006, 21315826.
99. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004, 324(1):269-275. 10.1016/j.bbrc.2004.09.047, 15465013.
100. Pedersen PL. The cancer cell's " power plants" as promising therapeutic targets: an overview. J Bioenerg Biomembr 2007, 39(1):1-12. 10.1007/s10863-007-9070-5, 17404823.
101. Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Geschwind JF. 3-Bromopyruvate: a New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy. Curr Pharm Biotechnol 2010, 11(5):510-517. 10.2174/138920110791591427, 20420565.
102. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res 2013, 33(1):13-20.
103. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, Vali M. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 2009, 29(12):4909-4918. 3743725, 20044597.
104. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, Da Poian AT, Galina A. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 2009, 417(3):717-726. 10.1042/BJ20080805, 18945211.
105. Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, Jansen-Durr P, Eigenbrodt E, Zwerschke W. Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer 2008, 123(2):312-321. 10.1002/ijc.23512, 18425820.
106. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44(27):9417-9429. 10.1021/bi0474923, 15996096.
107. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011, 30(42):4297-4306. 10.1038/onc.2011.137, 21516121.
108. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 2012, 209(2):217-224. 10.1084/jem.20111487, 3280873, 22271574.
109. Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 2010, 79(8):1118-1124. 10.1016/j.bcp.2009.12.003, 2823991, 20005212.
110. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010, 107(5):2037-2042. 10.1073/pnas.0914433107, 2836706, 20133848.
111. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, Ledoux SP, Tan M. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer 2010, 9:33. 2829492, 20144215.
112. Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, Monterey MD, Galloway MP, Sloan AE, Mathupala SP. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia 2011, 13(7):620-632. 3132848, 21750656.
113. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010, 52(2):762-773. 10.1002/hep.23725, 20564355.
114. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002, 62(14):3909-3913.
115. Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JF. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 2007, 18(1 Pt 1):95-101.
116. Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Ventura VP, Khwaja A, Acha-Ngwodo O, Shanmugasundaram G, Syed L, Wahl RL, Geschwind JF. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther 2008, 327(1):32-37. 10.1124/jpet.108.141093, 2760588, 18591216.
117. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, Hutchins AW, Gultekin Y, Peterson TR, Carette JE, Brummelkamp TR, Clish CB, Sabatini DM. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet 2013, 45(1):104-108. 3530647, 23202129.
118. Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, Hall NC, Koch RM, Cheng H, Knopp MV, Sun D. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 2008, 14(6):1831-1839. 10.1158/1078-0432.CCR-07-1607, 18347186.
119. Filomeni G, Cardaci S, Da Costa Ferreira AM, Rotilio G, Ciriolo MR. Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. Biochem J 2011, 437(3):443-453. 10.1042/BJ20110510, 21548882.
120. Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A, Oda A, Amou H, Nakamura S, Harada T, Fujii S, Kagawa K, Takeuchi K, Sakai A, Ozaki S, Okano K, Nakamura T, Itoh K, Matsumoto T, Abe M. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One 2011, 6(11):e27222. 10.1371/journal.pone.0027222, 3206937, 22073292.
121. Beneteau M, Zunino B, Jacquin MA, Meynet O, Chiche J, Pradelli LA, Marchetti S, Cornille A, Carles M, Ricci JE. Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. Proc Natl Acad Sci U S A 2012, 109(49):20071-20076. 10.1073/pnas.1206360109, 3523878, 23169636.